Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Bipartisan Budget Act of 2018
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - Bipartisan Budget Act - HR 1892 - Medicare Part D
ADHD Awareness *Drug Values -DEA processes and re-exportation -FDA Funding -Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -Expanded Access -Rare Disease awareness -Right to Try legislation (S. 204, H.R. 878, and H.R. 2368) -Newborn Screening
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2018 · second_quarter · 2A
HR 2587/S1194: Medical Nutrition Equity Act of 2017 HR6: Support for Patients and Communities Act 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
ADHD Awareness *Drug Values -DEA processes and re-exportation -FDA Funding -Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -Expanded Access -Rare Disease awareness -Right to Try legislation (S. 204, H.R. 878, and H.R. 2368) -Newborn Screening
Source: Senate LDA
ADHD Awareness *Drug Values -DEA processes and re-exportation -FDA Funding -Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -Expanded Access -Rare Disease awareness -Right to Try legislation (S. 204, H.R. 878, and H.R. 2368) -Newborn Screening
Medical Nutrition Equity Act of 2017
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
HR 2587/S1194: Medical Nutrition Equity Act of 2017 HR6: Support for Patients and Communities Act 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
Medical Nutrition Equity Act of 2017
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
HR 2587/S1194: Medical Nutrition Equity Act of 2017 HR6: Support for Patients and Communities Act 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
Medicare IVIG Access Enhancement Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - HR 4724: Medicare IVIG Access Enhancement Act - Medicare Part D
Medicare IVIG Access Enhancement Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - HR 4724: Medicare IVIG Access Enhancement Act - Medicare Part D
SUPPORT for Patients and Communities Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
HR 2587/S1194: Medical Nutrition Equity Act of 2017 HR6: Support for Patients and Communities Act 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
SUPPORT for Patients and Communities Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
HR 2587/S1194: Medical Nutrition Equity Act of 2017 HR6: Support for Patients and Communities Act 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
ADHD Awareness *Drug Values -DEA processes and re-exportation -FDA Funding -Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -Expanded Access -Rare Disease awareness -Right to Try legislation (S. 204, H.R. 878, and H.R. 2368) -Newborn Screening
ADHD Awareness *Drug Values -DEA processes and re-exportation -FDA Funding -Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -Expanded Access -Rare Disease awareness -Right to Try legislation (S. 204, H.R. 878, and H.R. 2368) -Newborn Screening
Medical Nutrition Equity Act of 2017
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
HR 2587/S1194: Medical Nutrition Equity Act of 2017 HR6: Support for Patients and Communities Act 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
Medical Nutrition Equity Act of 2017
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
HR 2587/S1194: Medical Nutrition Equity Act of 2017 HR6: Support for Patients and Communities Act 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
ADHD Awareness *Drug Values -DEA processes and re-exportation -FDA Funding -Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -Expanded Access -Rare Disease awareness -Right to Try legislation (S. 204, H.R. 878, and H.R. 2368) -Newborn Screening
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
ADHD Awareness *Drug Values -DEA processes and re-exportation -FDA Funding -Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -Expanded Access -Rare Disease awareness -Right to Try legislation (S. 204, H.R. 878, and H.R. 2368) -Newborn Screening
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - HR 4724: Medicare IVIG Access Enhancement Act - Medicare Part D
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - Bipartisan Budget Act - HR 1892 - Medicare Part D
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - HR 4724: Medicare IVIG Access Enhancement Act - Medicare Part D
Medicare IVIG Demonstration Extension Act of 2017
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - Affordable Care Act Medicaid Expansion - Medicare IVIG Access Act Reauthorization HR 3172 - Medicare Part D
Medicare IVIG Demonstration Extension Act of 2017
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - Affordable Care Act Medicaid Expansion - Medicare IVIG Access Act Reauthorization HR 3172 - Medicare Part D
Medicare IVIG Demonstration Extension Act of 2017
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - Affordable Care Act Medicaid Expansion - Medicare IVIG Access Act Reauthorization HR 3172 - Medicare Part D
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - Affordable Care Act Medicaid Expansion - Medicare IVIG Access Act Reauthorization HR 3172 - Medicare Part D
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - Affordable Care Act Medicaid Expansion - Medicare IVIG Access Act Reauthorization HR 3172 - Medicare Part D
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - Affordable Care Act Medicaid Expansion - Medicare IVIG Access Act Reauthorization HR 3172 - Medicare Part D
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - Affordable Care Act Medicaid Expansion
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration
H.R. 6, the 21st Century Cures Act: To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes. 340B Drug Discount Program Orphan Drug Act Biosimilars Gene Therapy Drug Pricing ____________________________________ Titles: S.2689 - 114th Congress (2015-2016) Short Titles: Short Titles - Senate Short Titles as Introduced: REGROW Act Reliable and Effective Growth for Regenerative Health Options that Improve Wellness Official Titles: Official Titles - Senate Official Titles as Introduced: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to cellular therapies.
H.R. 6, the 21st Century Cures Act: To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes. 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing ____________________________________ Titles: S.2689 - 114th Congress (2015-2016) Short Titles: Short Titles - Senate Short Titles as Introduced: REGROW Act Reliable and Effective Growth for Regenerative Health Options that Improve Wellness Official Titles: Official Titles - Senate Official Titles as Introduced: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to cellular therapies.
H.R. 6, the 21st Century Cures Act: To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes. 340B Drug Discount Program Orphan Drug Act Biosimilars Gene Therapy Drug Pricing ____________________________________ Titles: S.2689 - 114th Congress (2015-2016) Short Titles: Short Titles - Senate Short Titles as Introduced: REGROW Act Reliable and Effective Growth for Regenerative Health Options that Improve Wellness Official Titles: Official Titles - Senate Official Titles as Introduced: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to cellular therapies.
Medicare Home Infusion Site of Care Act of 2015
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
S. 275/HR. 605: Medicare Home Infusion Site of Care Act of 2015 Amends title XVIII (Medicare) of the Social Security Act to authorize Medicare coverage of home infusion therapy and home infusion drugs. Directs the Secretary of Health and Human Services to implement the Medicare home infusion therapy benefit in a manner that ensures that: (1) Medicare beneficiaries have timely and appropriate access to infusion therapy in their homes, and (2) there is rapid and seamless coordination between drug coverage under Medicare part D (Voluntary Prescription Drug Benefit Program) and home infusion therapy services coverage under Medicare part B (Supplemental Security Income) (SSI) to avoid the filing of duplicative or otherwise improper claims. Medicare coverage and reimbursement Medicare Part B drug payment model demonstration
Medicare Home Infusion Site of Care Act of 2015
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
S. 275/HR. 605: Medicare Home Infusion Site of Care Act of 2015 Amends title XVIII (Medicare) of the Social Security Act to authorize Medicare coverage of home infusion therapy and home infusion drugs. Directs the Secretary of Health and Human Services to implement the Medicare home infusion therapy benefit in a manner that ensures that: (1) Medicare beneficiaries have timely and appropriate access to infusion therapy in their homes, and (2) there is rapid and seamless coordination between drug coverage under Medicare part D (Voluntary Prescription Drug Benefit Program) and home infusion therapy services coverage under Medicare part B (Supplemental Security Income) (SSI) to avoid the filing of duplicative or otherwise improper claims. Medicare coverage and reimbursement Medicare Part B drug payment model demonstration
Medicare Home Infusion Site of Care Act of 2015
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
S. 275/HR. 605: Medicare Home Infusion Site of Care Act of 2015 Amends title XVIII (Medicare) of the Social Security Act to authorize Medicare coverage of home infusion therapy and home infusion drugs. Directs the Secretary of Health and Human Services to implement the Medicare home infusion therapy benefit in a manner that ensures that: (1) Medicare beneficiaries have timely and appropriate access to infusion therapy in their homes, and (2) there is rapid and seamless coordination between drug coverage under Medicare part D (Voluntary Prescription Drug Benefit Program) and home infusion therapy services coverage under Medicare part B (Supplemental Security Income) (SSI) to avoid the filing of duplicative or otherwise improper claims. Medicare coverage and reimbursement Medicare Part B drug payment model demonstration
H.R. 6, the 21st Century Cures Act: To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes. 340B Drug Discount Program Orphan Drug Act Biosimilars Gene Therapy Drug Pricing ____________________________________ Titles: S.2689 - 114th Congress (2015-2016) Short Titles: Short Titles - Senate Short Titles as Introduced: REGROW Act Reliable and Effective Growth for Regenerative Health Options that Improve Wellness Official Titles: Official Titles - Senate Official Titles as Introduced: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to cellular therapies.
H.R. 6, the 21st Century Cures Act: To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes. 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing ____________________________________ Titles: S.2689 - 114th Congress (2015-2016) Short Titles: Short Titles - Senate Short Titles as Introduced: REGROW Act Reliable and Effective Growth for Regenerative Health Options that Improve Wellness Official Titles: Official Titles - Senate Official Titles as Introduced: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to cellular therapies.
H.R. 6, the 21st Century Cures Act: To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes. 340B Drug Discount Program Orphan Drug Act Biosimilars Gene Therapy Drug Pricing ____________________________________ Titles: S.2689 - 114th Congress (2015-2016) Short Titles: Short Titles - Senate Short Titles as Introduced: REGROW Act Reliable and Effective Growth for Regenerative Health Options that Improve Wellness Official Titles: Official Titles - Senate Official Titles as Introduced: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to cellular therapies.
Medicare Home Infusion Site of Care Act of 2015
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
S. 275/HR. 605: Medicare Home Infusion Site of Care Act of 2015 Amends title XVIII (Medicare) of the Social Security Act to authorize Medicare coverage of home infusion therapy and home infusion drugs. Directs the Secretary of Health and Human Services to implement the Medicare home infusion therapy benefit in a manner that ensures that: (1) Medicare beneficiaries have timely and appropriate access to infusion therapy in their homes, and (2) there is rapid and seamless coordination between drug coverage under Medicare part D (Voluntary Prescription Drug Benefit Program) and home infusion therapy services coverage under Medicare part B (Supplemental Security Income) (SSI) to avoid the filing of duplicative or otherwise improper claims. Medicare coverage and reimbursement Medicare Part B drug payment model demonstration
Medicare Home Infusion Site of Care Act of 2015
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
S. 275/HR. 605: Medicare Home Infusion Site of Care Act of 2015 Amends title XVIII (Medicare) of the Social Security Act to authorize Medicare coverage of home infusion therapy and home infusion drugs. Directs the Secretary of Health and Human Services to implement the Medicare home infusion therapy benefit in a manner that ensures that: (1) Medicare beneficiaries have timely and appropriate access to infusion therapy in their homes, and (2) there is rapid and seamless coordination between drug coverage under Medicare part D (Voluntary Prescription Drug Benefit Program) and home infusion therapy services coverage under Medicare part B (Supplemental Security Income) (SSI) to avoid the filing of duplicative or otherwise improper claims. Medicare coverage and reimbursement Medicare Part B drug payment model demonstration
Medicare Home Infusion Site of Care Act of 2015
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
S. 275/HR. 605: Medicare Home Infusion Site of Care Act of 2015 Amends title XVIII (Medicare) of the Social Security Act to authorize Medicare coverage of home infusion therapy and home infusion drugs. Directs the Secretary of Health and Human Services to implement the Medicare home infusion therapy benefit in a manner that ensures that: (1) Medicare beneficiaries have timely and appropriate access to infusion therapy in their homes, and (2) there is rapid and seamless coordination between drug coverage under Medicare part D (Voluntary Prescription Drug Benefit Program) and home infusion therapy services coverage under Medicare part B (Supplemental Security Income) (SSI) to avoid the filing of duplicative or otherwise improper claims. Medicare coverage and reimbursement Medicare Part B drug payment model demonstration
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - HR 4724: Medicare IVIG Access Enhancement Act - Medicare Part D
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2018 · second_quarter · Q2
HR 2587/S1194: Medical Nutrition Equity Act of 2017 HR6: Support for Patients and Communities Act 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - HR 4724: Medicare IVIG Access Enhancement Act - Medicare Part D
ADHD Awareness *Drug Values -DEA processes and re-exportation -FDA Funding -Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -Expanded Access -Rare Disease awareness -Right to Try legislation (S. 204, H.R. 878, and H.R. 2368) -Newborn Screening
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2018 · first_quarter · Q1
340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - Bipartisan Budget Act - HR 1892 - Medicare Part D
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2017 · third_quarter · 3A
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - Affordable Care Act Medicaid Expansion - Medicare IVIG Access Act Reauthorization HR 3172 - Medicare Part D
340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2017 · fourth_quarter · Q4
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - Affordable Care Act Medicaid Expansion - Medicare IVIG Access Act Reauthorization HR 3172 - Medicare Part D
340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2017 · third_quarter · Q3
340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - Affordable Care Act Medicaid Expansion - Medicare IVIG Access Act Reauthorization HR 3172 - Medicare Part D
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2017 · second_quarter · Q2
340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - Affordable Care Act Medicaid Expansion
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2017 · first_quarter · Q1
340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2016 · fourth_quarter · Q4
H.R. 6, the 21st Century Cures Act: To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes. 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing ____________________________________ Titles: S.2689 - 114th Congress (2015-2016) Short Titles: Short Titles - Senate Short Titles as Introduced: REGROW Act Reliable and Effective Growth for Regenerative Health Options that Improve Wellness Official Titles: Official Titles - Senate Official Titles as Introduced: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to cellular therapies.
S. 275/HR. 605: Medicare Home Infusion Site of Care Act of 2015 Amends title XVIII (Medicare) of the Social Security Act to authorize Medicare coverage of home infusion therapy and home infusion drugs. Directs the Secretary of Health and Human Services to implement the Medicare home infusion therapy benefit in a manner that ensures that: (1) Medicare beneficiaries have timely and appropriate access to infusion therapy in their homes, and (2) there is rapid and seamless coordination between drug coverage under Medicare part D (Voluntary Prescription Drug Benefit Program) and home infusion therapy services coverage under Medicare part B (Supplemental Security Income) (SSI) to avoid the filing of duplicative or otherwise improper claims. Medicare coverage and reimbursement Medicare Part B drug payment model demonstration
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2016 · third_quarter · Q3
Article 29 Working Party on the Protection of Individuals ("WP29") statement regarding the landmark CJEU ruling invalidating Safe Harbor as a mechanism of establishing adequacy supporting EU-US data transfers.
H.R. 6, the 21st Century Cures Act: To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes. 340B Drug Discount Program Orphan Drug Act Biosimilars Gene Therapy Drug Pricing ____________________________________ Titles: S.2689 - 114th Congress (2015-2016) Short Titles: Short Titles - Senate Short Titles as Introduced: REGROW Act Reliable and Effective Growth for Regenerative Health Options that Improve Wellness Official Titles: Official Titles - Senate Official Titles as Introduced: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to cellular therapies.
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2016 · second_quarter · Q2
S. 275/HR. 605: Medicare Home Infusion Site of Care Act of 2015 Amends title XVIII (Medicare) of the Social Security Act to authorize Medicare coverage of home infusion therapy and home infusion drugs. Directs the Secretary of Health and Human Services to implement the Medicare home infusion therapy benefit in a manner that ensures that: (1) Medicare beneficiaries have timely and appropriate access to infusion therapy in their homes, and (2) there is rapid and seamless coordination between drug coverage under Medicare part D (Voluntary Prescription Drug Benefit Program) and home infusion therapy services coverage under Medicare part B (Supplemental Security Income) (SSI) to avoid the filing of duplicative or otherwise improper claims. Medicare coverage and reimbursement Medicare Part B drug payment model demonstration
H.R. 6, the 21st Century Cures Act: To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes. 340B Drug Discount Program Orphan Drug Act Biosimilars Gene Therapy Drug Pricing ____________________________________ Titles: S.2689 - 114th Congress (2015-2016) Short Titles: Short Titles - Senate Short Titles as Introduced: REGROW Act Reliable and Effective Growth for Regenerative Health Options that Improve Wellness Official Titles: Official Titles - Senate Official Titles as Introduced: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to cellular therapies.
Filing targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, SENATE
S. 275/HR. 605: Medicare Home Infusion Site of Care Act of 2015 Amends title XVIII (Medicare) of the Social Security Act to authorize Medicare coverage of home infusion therapy and home infusion drugs. Directs the Secretary of Health and Human Services to implement the Medicare home infusion therapy benefit in a manner that ensures that: (1) Medicare beneficiaries have timely and appropriate access to infusion therapy in their homes, and (2) there is rapid and seamless coordination between drug coverage under Medicare part D (Voluntary Prescription Drug Benefit Program) and home infusion therapy services coverage under Medicare part B (Supplemental Security Income) (SSI) to avoid the filing of duplicative or otherwise improper claims. Medicare coverage and reimbursement Medicare Part B drug payment model demonstration
Orphan drug tax credit
Filing targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE